State Board of Administration of Florida Retirement System Purchases 6,060 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

State Board of Administration of Florida Retirement System lifted its position in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTLGet Rating) by 55.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 17,009 shares of the company’s stock after purchasing an additional 6,060 shares during the period. State Board of Administration of Florida Retirement System’s holdings in Zentalis Pharmaceuticals were worth $478,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in ZNTL. Assetmark Inc. lifted its position in shares of Zentalis Pharmaceuticals by 337.3% during the second quarter. Assetmark Inc. now owns 1,054 shares of the company’s stock valued at $30,000 after purchasing an additional 813 shares in the last quarter. Captrust Financial Advisors raised its position in Zentalis Pharmaceuticals by 15,160.0% in the first quarter. Captrust Financial Advisors now owns 763 shares of the company’s stock worth $35,000 after acquiring an additional 758 shares during the period. US Bancorp DE raised its position in Zentalis Pharmaceuticals by 378.9% in the first quarter. US Bancorp DE now owns 1,451 shares of the company’s stock worth $67,000 after acquiring an additional 1,148 shares during the period. Point72 Hong Kong Ltd bought a new stake in Zentalis Pharmaceuticals in the first quarter worth about $72,000. Finally, Prospera Financial Services Inc bought a new stake in Zentalis Pharmaceuticals in the first quarter worth about $104,000.

Analyst Ratings Changes

ZNTL has been the topic of several research reports. Guggenheim lowered their price objective on shares of Zentalis Pharmaceuticals from $55.00 to $28.00 and set a “buy” rating on the stock in a research report on Friday, November 11th. Oppenheimer lowered their price objective on shares of Zentalis Pharmaceuticals from $80.00 to $50.00 and set an “outperform” rating on the stock in a research report on Thursday, November 10th. SVB Leerink lowered their price objective on shares of Zentalis Pharmaceuticals from $42.00 to $27.00 and set an “outperform” rating on the stock in a research report on Thursday, November 10th. Morgan Stanley lowered their price objective on shares of Zentalis Pharmaceuticals from $60.00 to $55.00 and set an “overweight” rating on the stock in a research report on Friday, November 11th. Finally, HC Wainwright reduced their target price on shares of Zentalis Pharmaceuticals from $120.00 to $55.00 and set a “buy” rating for the company in a research note on Wednesday, August 10th. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $45.88.

Insider Transactions at Zentalis Pharmaceuticals

In related news, President Cam Gallagher sold 12,500 shares of the business’s stock in a transaction that occurred on Thursday, September 15th. The shares were sold at an average price of $25.26, for a total transaction of $315,750.00. Following the completion of the transaction, the president now owns 454,385 shares of the company’s stock, valued at $11,477,765.10. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders sold 62,500 shares of company stock worth $1,469,125 over the last quarter. Corporate insiders own 19.90% of the company’s stock.

Zentalis Pharmaceuticals Stock Up 5.2 %

ZNTL opened at $22.20 on Friday. The company has a market capitalization of $1.27 billion, a price-to-earnings ratio of -4.70 and a beta of 1.90. The firm has a 50-day moving average price of $22.88 and a 200-day moving average price of $25.22. Zentalis Pharmaceuticals, Inc. has a twelve month low of $17.33 and a twelve month high of $85.95.

Zentalis Pharmaceuticals Profile

(Get Rating)

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker.

Featured Articles

Want to see what other hedge funds are holding ZNTL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTLGet Rating).

Institutional Ownership by Quarter for Zentalis Pharmaceuticals (NASDAQ:ZNTL)

Receive News & Ratings for Zentalis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zentalis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.